The TULSA procedure, performed using Profound’s TULSA-PRO® system, is a potential treatment for the entire prostate disease spectrum, including low-, intermediate-, or high-risk prostate cancer, benign prostatic hyperplasia, and patients requiring salvage therapy for radio-recurrent localized prostate cancer. The procedure employs real-time MR guidance for precision, preserving patients’ urinary continence and sexual function while killing the targeted prostate tissue via precise sound absorption technology.
Key takeaways:
- Profound Medical Corp. is set to unveil its third TULSA-AI® software module, UA Alignment Assistant, which streamlines the alignment of the ultrasound applicator during the TULSA procedure.
- The TULSA procedure, performed using Profound’s TULSA-PRO® system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum.
- The procedure employs real-time MR guidance for precision to preserve patients’ urinary continence and sexual function, while killing the targeted prostate tissue via precise sound absorption technology.
- Profound is also commercializing Sonalleve®, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.